Perrigo (PRGO)
Health Care · Consumer healthcare and specialty pharmaceuticals · NYSE
A struggling diversified consumer and prescription healthcare manufacturer navigating portfolio restructuring and strategic divestitures amid margin pressure and competitive headwinds.
What Perrigo does
Perrigo is a global healthcare company that develops, manufactures, and distributes over-the-counter consumer healthcare products, prescription medications, and nutritional products across multiple markets. The company operates through consumer self-care and prescription business segments, serving retail customers and consumers worldwide. Perrigo is currently undergoing a strategic review involving proposed divestitures of its Dermacosmetics branded business and other business units to reshape its portfolio.
Themes: ["Consumer self-care / OTC healthcare","Prescription pharmaceuticals","Nutritional supplements","Dermatology / cosmetics","Rare diseases"]
Fundamentals
- Price$10.41 as of 2026-07-09 close
- Market cap$1.5B as of 2026-07-10
- 1-year return-61.8% as of 2026-07-09 close
- Net margin-43.5% as of 2026-07-10
- Gross margin+34.2% as of 2026-07-10
- ROE-50.6% as of 2026-07-10
- Debt / equity1.45 as of 2026-07-10
- Revenue growth (YoY)-3.6% as of 2026-07-10
- Revenue CAGR (3y)-1.5% SEC XBRL
- Beta0.53 as of 2026-07-10
Dividend: yield +11.1%; 5-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Inability to complete proposed divestitures of Dermacosmetics business and other units, including receipt of required regulatory and works council approvals and counterparty performance on deferred payments","Severe pricing pressures from customers and consumers, combined with intensifying competition from larger competitors with greater marketing resources and market share in key product categories","Supply chain disruptions and geopolitical risks from armed conflicts (Ukraine, Middle East), trade sanctions, and tariffs that impact manufacturing and operations; product recall risks and regulatory approval uncertainties"]
Competitors & peers
- Church & Dwight (CHD)
- Prestige Consumer Healthcare (PBH)
- Procter & Gamble Health (PG)
- Reckitt Benckiser Group (RBGLY)
- Chattem (part of Sanofi)
- Haleon (HLNKY)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.